The effect of the immunosuppressant FK‐506 on alternate pathways of T cell activation

European Journal of Immunology - Tập 21 Số 2 - Trang 439-445 - 1991
Barbara E. Bierer1,2,3,4, Stuart L. Schreiber5, Steven J. Burakoff6,3
1Dana-Farber Cancer Institute, Hematology Division, Boston
2§Department of Medicine, Harvard Medical School, Boston
3Division of Pediatric Oncology, Boston
4Recipient of a McDonnell Scholar Award from the James S. McDonnell Foundation and of a Clinician-Scientist Award from the American Heart Association.
5Department of Medicine, Brigham and Women's Hospital, Department of Chemistry, Harvard University, Boston
6Department of Pediatrics, Harvard Medical School, Boston

Tóm tắt

Abstract

Structurally unrelated, FK‐506 and cyclosporin (CsA) bind to and inhibit the action of distinct cytoplasmic receptors, FK‐506‐binding protein (FKBP) and cyclophilin (CyP), respectively. These receptors, termed immunophilins, share no sequence similarity, and yet both have been demonstrated to be capable of catalyzing the cis‐trans isomerization of peptidyl‐prolyl bonds (rotamase activity). Because FK‐506 and CsA bind to different intracellular target structures, we investigated the spectrum of action of FK‐506, in comparison to CsA, on T cell activation. We have shown that FK‐506, like CsA, is able to inhibit T cell activation mediated not only by the T cell receptor‐CD3 complex, but also via another surface molecule, CD2. T cell proliferation, stimulation of interleukin 2 production, and induction of apoptosis were all sensitive to inhibition by both FK‐506 and CsA. With each parameter of activation, FK‐506 is approximately 10‐100‐fold more effective than CsA. In contrast, FK‐506 did not affect T cell proliferation induced by anti‐CD28 monoclonal antibody in the presence of phorbol 12‐myristate 13‐acetate. This CD28 pathway, however, was inhibitable by a structural homolog of FK‐506, rapamycin, demonstrating that the mechanism of action of FK‐506 has specificity. These data suggest that immunophilins or the complex of drug coupled to immunophilin (i.e. FK‐506/FKBP, CsA/CyP) are involved in and regulate selective pathways of T cell stimulation.

Từ khóa


Tài liệu tham khảo

10.1016/0167-5699(89)90057-1

10.7164/antibiotics.40.1249

10.7164/antibiotics.40.1256

10.1016/S0140-6736(89)91014-3

10.4049/jimmunol.143.2.718

10.1097/00007890-198902000-00034

10.4049/jimmunol.139.6.1797

Zeevi A., 1988, Transplant. Proc., 20, 22D

10.7164/antibiotics.28.727

10.7164/antibiotics.31.539

10.1139/y77-007

10.1126/science.6238408

10.1038/337473a0

10.1038/337476a0

10.1038/341758a0

10.1038/341755a0

10.1038/346671a0

10.1126/science.6334364

10.1073/pnas.81.16.5214

10.1084/jem.163.4.922

10.1126/science.2595372

10.1016/0092-8674(84)90039-4

Brottier P., 1985, J. Immunol., 135, 1624, 10.4049/jimmunol.135.3.1624

10.4049/jimmunol.137.4.1097

10.1073/pnas.83.8.2614

Holter W., 1988, J. Immunol., 140, 1043, 10.4049/jimmunol.140.4.1043

10.1042/bj2200345

10.1038/308693a0

10.1084/jem.161.6.1513

10.1084/jem.162.3.823

Mills G. B., 1985, J. Immunol., 134, 1344

Ledbetter J. A., 1986, J. Immunol., 137, 3299, 10.4049/jimmunol.137.10.3299

10.1002/eji.1830190524

10.1073/pnas.85.4.1194

McMichael A. J., 1987, Leukocyte Typing III

10.1007/978-1-4613-8587-5_4

10.1007/BF01561573

10.1073/pnas.84.5.1374

10.4049/jimmunol.120.6.2027

10.1128/MCB.7.12.4472

10.1002/eji.1830190515

10.1084/jem.165.1.173

Mercep M., 1988, J. Immunol., 140, 324, 10.4049/jimmunol.140.1.324

10.4049/jimmunol.142.11.4085

10.1038/328351a0

10.1097/00007890-199006000-00028

10.1038/339625a0

10.1126/science.2783497

10.4049/jimmunol.137.3.819

10.1073/pnas.86.4.1333

10.1016/0167-5699(90)90085-N

10.4049/jimmunol.144.1.251

10.4049/jimmunol.144.4.1418

10.1038/334625a0

10.1126/science.3259335

10.1126/science.2531464

10.1016/0092-8674(87)90568-X

10.1038/333742a0

10.1038/332040a0

10.1038/337181a0

10.1073/pnas.87.23.9231

10.1126/science.1700475